Summary: After repeated subcutaneous administration of 14C-clonidine to male rats once a day for 21 days at a dose of 1 mg/kg/day, the absorption, distribution and excretion of radioactivity were investigated .
Introduction
M-5041T is a new transdermal delivery system for clonidine, being under development to be used for hyper tension therapy. As a part of the investigation on this system, the metabolic fate of clonidine in animals was studied using [imidazolidine-2-14C] clonidine (14C-cloni dine) as a tracerl,2). This paper presents the absorption, distribution and excretion of radioactivity after repeated subcutaneous administration of 14C-clonidine to male rats. Materials and Methods
Compounds 14C-Clonidine was synthesized by Chemsyn Science
Laboratories and purified by Daiichi Pure Chemicals Co., Ltd. The structure and labelled position were shown in the previous paper.') The specific activity was 8.26 to 9.08 MBq/mg and the radiochemical purity was more than 96% determined by the thin-layer chro matography as described previously.') Unlabelled cloni dine was purchased from Daiwa Pharmaceutical Co., Ltd.
2. Experimental Animals Male Sprague-Dawley strain SPF rats of 7 to 8 weeks old weighing about 280 g (SLC Japan Inc.) were used. The rats were acclimatized before use as described previously.') Three animals were assigned to each ex perimental group but one was used for the whole body autoradiography.
Preparation of Dosing Solution and Administra
tion of Test Article 14C-Clonidine mixed with unlabelled clonidine was dis solved in saline to contain 0.5 mg/ml (about 0.46 MBq/ ml). This solution was administered subcutaneously to the back of rats in a volume of 2 ml/kg once a day at fixed time for a maximum of 21 days.
Measurement of Radioactivity
Radioactivity in each sample was counted for 2 min with a liquid scintillation counter (LSC-903 or LSC 3600, Aloka). The counting efficiency was corrected by the channels ratio method using an external standard source.
Determination of Radioactivity Concentration in
Plasma The blood was withdrawn from the caudal vein at ev ery 24 hr after daily administration and at designated times after the 21st dosing of 14C-clonidine to male rats. The blood was centrifuged (1800 x g, 4°C, 15 min) to separate plasma and the radioactivity was counted as de scribed previously.') 6 . Whole Body Autoradiography Male rats were sacrificed by ether treatment after a 21 day period of daily subcutaneous administration of 14C-clonidine to male rats . Whole body autoradiograms were prepared as described previously.') 7. Determination of Radioactivity Concentration in
Tissue
Male rats were exsanguinated from the abdominal aor ta under ether anesthesia at 24 hr after the 7th and 14th administration of 14C-clonidine and at designated times after the 21st dosing. Then the tissues were excised and weighed. The radioactivity in the plasma, blood and tis sues was counted as described previously.')
The hematocrit value was measured and the distribu tion ratio in blood cells was calculated as described previously.') 8 . Determination of Radioactivity Excreted in Urine and Feces Male rats were placed in metabolic cages (KN-646B, Natsume) after daily administration of 14C-clonidine.
The excreted urine and feces were collected for every 24 hr after each administration and for every 24 hr until 168 hr after the 21st administration. At this time, the rats were sacrificed by ether treatment and the applica tion site (including skin and skeletal muscle) was ex cised. The radioactivity in the urine, feces, administra tion site and carcass was counted as described previously.')
Expression of Results
The radioactivity concentration was converted to the equivalent value of clonidine. Results were expressed as the mean values and standard deviations (S.D.). Phar macokinetic parameters were calculated from the mean values of three animals. Half-life was expressed as the apparent value that was calculated by the least square regression. Area under radioactivity concentration in plasma vs. time curve (AUC) was obtained by the trapezoidal method throughout the detectable time points and then by the extrapolation of the final phase to infinity as described previously.') To simulate plasma concentration for repeated administration from single dosing, two-compartment open model was chosen. The pharmacokinetic parameters for the single dose were cal culated by the nonlinear least square regression from the result obtained previously.') Results 
Radioactivity
Concentration in Plasma 14C-clonidine once a day for 21 days to male rats at a dose of 1 mg/kg/day. A calculated curve obtained from the single dose') was also shown in Fig. 1 . No marked variation was observed in the concentration of the plas ma with the number of dosing. The observed values agreed with the calculated curve. Fig. 2 shows the radioactivity concentrations in plas ma after single') and the 21st administration. The calcu lated curves were also shown in Fig. 2 . After the 21st dosing, the concentration reached a maximum (Cmax) of 205.0 ng/ml at 2 hr and then declined with half-lives of 7.9 hr between 4 and 24 hr and 76 hr between 48 and 120 hr. AUC was 4.58 ug • hr/ml. Compared with the profile after single administration,') the same level in the Tmax, 1.2 times higher in the Cmax, the comparable level in the half-life for the first phase, 2.1 times longer in the half-life for the second phase and 1.8 times larger in the AUC. The observed values obtained after the 21st ad ministration agreed with the calculated curve except a few points on the last phase. Fig. 3 shows the whole body autoradiograms after a 21 day period of daily subcutaneous administration of '4C-clonidine at a dose of 1 mg/kg/day to male rats . At 2 hr after administration, high level of radioactivity was found in the administration site, mandibular gland, exorbital lacrimal gland, intraorbital lacrimal gland, preputial gland, intestinal contents, urine in the bladder and gastric contents, followed by the levels in the kid ney, ligament, liver, nasal cavity, lung and bulbourethral gland.
Whole Body Autoradiograms
The other tissues except the fat showed higher radioactivity than the blood. At 8 and 24 hr, the overall radioactivity in the body decreased. The distribution pat tern was similar to that at 2 hr.
At 120 hr, some residual radioactivity was found in the preputial gland, aorta, thyroid gland and nasal cavi ty, followed by the trace in the liver, kidney, lung and in testinal contents. Table I shows the radioactivity concentrations in the tissues at 24 hr after the first (single')), 7th, 14th and 21st subcutaneous administration of 14C-clonidine to male rats at a daily dose of 1 mg/kg/day. Steady states were observed by the 21st administration in the exam ined tissues except the aorta. Compared the concentra tions in each tissue at 24 hr after the 21st administration with those after the first administration, 10 times was found in the aorta and less than 3.5 times in the others. Table II shows the radioactivity concentrations in the tissues after the 21st administration. Maximum concen trations were observed at 2 hr in all of the examined tis sues. At this time, the concentrations in the tissues ex cept the eyeball and fat were found higher than that in the plasma (217.5 ng/ml). High concentration was ob served in the kidney, mandibular gland and liver, which contained 12 to 15 times higher than that in the plasma.
Radioactivity Concentration in Tissue
Afterward, the radioactivities in most of the tissues were eliminated more rapidly than that in the plasma and decreased to less than 15% of their respective maxi ma at 24 hr after administration. At this time point, however, the concentration in the aorta decreased to about 80% of the maximum and in the thyroid gland, liver, blood and skin decreased to 19 to 38% of their respective maxima. At 720 hr, the concentrations were 67% of the maximum in the aorta, 6 to 9% in the thyroid gland and skin. The other tissues showed less than 3% or undetectable level.
The distribution ratio of radioactivity in the blood cells at 24 hr after daily administration achieved a steady state by the 21st dosing. After the last dosing, the ratio increased gradually with the elapse of time (Ta ble III). Feces  Fig. 4 shows the cumulative excretions of radioactivi ty in the urine and feces determined at every 24 hr dur ing and after a 21day period of daily subcutaneous ad ministration of 14C-clonidine at a dose of 1 mg/kg/day to male rats. The total excretion of radioactivity in the urine and feces during each 24 hr after daily administra tion was almost constant after the 2nd dosing, account ing for 93 to 98% of the cumulative dose. Within 168 hr after the last administration, 71.6 and 26A YO of the cu mulative dose were excreted in the urine and feces, re spectively, and the value of total excretion was 98.1% of the cumulative dose. At this time point, the residual radioactivity in the administration site was not detected and 0.3% of the cumulative dose remained in the car cass.
Excretion of Radioactivity in Urine and

Discussion
To investigate for accumulation of radioactivity, 14C clonidine was daily administered subcutaneously to male rats for 21 days. The observed radioactivity concen tration in plasma at every 24 hr after daily dosing agreed with the calculated curve obtained from the parameters for single dose. It suggests that the absorption and dispo sition of radioactivity have attained steady state. After the 21st administration, the observed values also agreed with the calculated curve except a few points on the last phase. It was considered that the nonlinear phenomenon would not occur by repeated administration.
The half-life for the last phase (48-120 hr) was 2.1 times longer. This slow elimination phase would result from the accumulation of a trace of radioactivity that could not be detected after single administration. As shown in the subsequent paper,3> relative amounts of metabolites in plasma increased with the elapse of time. Thus, some metabolites would have slow elimination rate and these metabolites would relate the slow elimina tion phase described above.
Accumulation of radioactivity was found in some or gans. At 24 hr after the 21st administration, the concen tration in the aorta was 10.4 times higher than that after the single administration.
The lung, thyroid gland, liver and skin showed also higher concentration, accounting for 2.4 to 3.5 times. While in the other tissues, they were about twice or less than twice of corresponding concen trations after the single administration.
As described in the subsequent paper3>, the residual radioactivity in the aorta after repeated administration of 14C-clonidine was analyzed. The radioactivity was lit tle extractable directly with methanol, but became ex tractable mostly after the hydrolysis with elastase. Therefore, it is considered that this radioactivity was tightly bound to protein in the aorta such as elastin.
However, the chemical structure of radioactivity in the latter methanol extract could not be identified. The tis sues that have high content of elastin, such as lung, skin and liver were also found the accumulation. Thus, the ac cumulated radioactivity in these tissues seems to bind to the elastin. On several compounds containing imidazole in their structure like clonidine, the accumulation of radioactivi ty in the aorta has been reported.4'5) A recent study has revealed that an oxidized metabolite of imidazole, im idazolone, bound covalently to elastin.6) A similar mechanism would concern the accumulation of radioac tivity after administration of 14C-clonidine in this study. On the chronic toxicity studies of clonidine, no histopathological change has been observed in the aorta on both microscopic and electron-microscopic examina tions. 7 The total excretion of radioactivity in the urine and feces was constant after the 2nd dosing, accounting for 93 to 98% of the cumulative dose. In the carcass, 0.3% of the cumulative dose remained at 168 hr after the 21st administration. Therefore, it was confirmed that most of Table II Radioactivity concentrations in tissues after a 21 day period of daily subcutaneous administration of 14C-clonidine to male rats (dose: 1 mg/kg/day) the radioactivity was excreted rapidly after repeated sub cutaneous administration and a trace of radioactivity was accumulated in some tissues.
In conclusion, the effect of repeated administration on the absorption, distribution and excretion of clonidine was investigated after subcutaneous administration of 14C-clonidine to male rats . Although the radioactivity ac cumulated in some tissues, most of the radioactivity ad ministered was excreted rapidly.
Table III Distribution ratio of radioactivity in blood cells after daily subcutaneous administration of 14C clonidine to male rats (dose: 1 mg/kg/day) Fig. 4 Cumulative excretions of radioactivity in urine and feces during and after a 21 day period of daily subcutaneous ad ministration of 14C-clonidine to male rats (dose: 1 mg/kg/day) Data are expressed as the mean values ±S.D. of three animals. All samples were collected for a 24 hr period after daily dosing and then every 24 hr after the final dose.
